-
New ADCs bring new questions in EGFR NSCLC and beyond Ann. Oncol. (IF 50.5) Pub Date : 2024-03-12 S. Scott, B. Levy
-
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment? Ann. Oncol. (IF 50.5) Pub Date : 2024-03-12 E. Agostinetto, L. Buisseret, R. Salgado, M. Kok, M. Ignatiadis
-
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-02-29 G. Bogani, B.J. Monk, M.A. Powell, S.N. Westin, B. Slomovitz, K.N. Moore, R.N. Eskander, F. Raspagliesi, M.-P. Barretina-Ginesta, N. Colombo, M.R. Mirza
Immunotherapy has transformed the endometrial cancer treatment landscape, particularly for those exhibiting mismatch repair deficiency [MMRd/microsatellite instability-hypermutated (MSI-H)]. A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612)
-
Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-02-24 R.S. Laskar, C. Qu, J.R. Huyghe, T. Harrison, R.B. Hayes, Y. Cao, P.T. Campbell, R. Steinfelder, F.R. Talukdar, H. Brenner, S. Ogino, S. Brendt, D.T. Bishop, D.D. Buchanan, A.T. Chan, M. Cotterchio, S.B. Gruber, A. Gsur, B. van Guelpen, M.A. Jenkins, T.O. Keku, B.M. Lynch, L. Le Marchand, R.M. Martin, K. McCarthy, V. Moreno, R. Pearlman, M. Song, K.K. Tsilidis, P. Vodička, M.O. Woods, K. Wu, L. Hsu
The incidence of early-onset colorectal cancer (EOCRC; diagnosed <50 years of age) is rising globally; however, the causes underlying this trend are largely unknown. Colorectal cancer (CRC) has strong genetic and environmental determinants, yet common genetic variants and causal modifiable risk factors underlying EOCRC are unknown. We conducted the first EOCRC-specific genome-wide association study
-
Caution against overoptimistic findings Ann. Oncol. (IF 50.5) Pub Date : 2024-02-21 S. Kouzan, S. Chevret
-
-
Hit hard and remove treatment – this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave Ann. Oncol. (IF 50.5) Pub Date : 2024-02-21 Professor I. Glimelius
-
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Ann. Oncol. (IF 50.5) Pub Date : 2024-02-19 B. Sangro, S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen, M. Yarchoan, E.N. De Toni, J. Furuse, Y.K. Kang, P.R. Galle, L. Rimassa, A. Heurgué, V.C. Tam, T. Van Dao, S.C. Thungappa, V. Breder, Y. Ostapenko, M. Reig, M. Makowsky, M.J. Paskow, C. Gupta, J.F. Kurland, A. Negro, G.K. Abou-Alfa, HIMALAYA investigators, Sergio Azevedo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Bragagnoli
In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA. Participants with uHCC and no previous systemic treatment
-
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 Ann. Oncol. (IF 50.5) Pub Date : 2024-02-17 L. Pusztai, C. Denkert, J. O’Shaughnessy, J. Cortes, R. Dent, H. McArthur, S. Kümmel, J. Bergh, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P.A. Fasching, F. Cardoso, Y. Zhu, W. Pan, K. Tryfonidis, P. Schmid
KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual
-
Peritoneal Effusion: An Uncommon Adverse Effects of Selective RET Inhibitors Ann. Oncol. (IF 50.5) Pub Date : 2024-02-16 C. Belli, G. Curigliano
-
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) Ann. Oncol. (IF 50.5) Pub Date : 2024-02-15 D. Yue, W. Wang, H. Liu, Q. Chen, C. Chen, L. Liu, P. Zhang, G. Zhao, F. Yang, G. Han, Y. Cheng, B. Yu, Y. Yang, H. Chen, J. Jiang, B. Yao, S. Wang, R. Wang, W. Zheng, C. Wang
-
The co-expression of antigen targets as a rationale for ADCs combination in urothelial cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-02-14 F. BERTUCCI, A. DE NONNEVILLE, P. FINETTI, A. COHENDET, A. GUILLE, E. MAMESSIER
-
Centralisation of care improves overall survival for sarcoma patients Ann. Oncol. (IF 50.5) Pub Date : 2024-02-10 A. Napolitano, K. Thway, P. Huang, R.L. Jones
-
Does ‘B’ stand for ‘Benefit ?’ Decoding the B-cell neighborhood in head and neck cancer for predicting therapeutic response to PD1 inhibitors Ann. Oncol. (IF 50.5) Pub Date : 2024-02-09 B.B.Y. Ma, D.W.T. Lim
-
-
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-02-07 C. Rolfo, A. Russo
-
-
P9-2 Effect of Ayurveda based CAM therapy on quality of life in elderly patient with hepatic cell carcinoma Ann. Oncol. (IF 50.5) Pub Date : 2024-02-06 Yogesh Bendale, Avinash Kadam, Poonam Birari-Gawande, Anandrao Patil, Pravin Gund, Harshala Jagtap
-
Reply to Bhatt and colleagues Ann. Oncol. (IF 50.5) Pub Date : 2024-02-03 M. Di Maio
Abstract not available
-
Importance of pain management in cancer patients and survivors Ann. Oncol. (IF 50.5) Pub Date : 2024-02-02 K. Bhatt, A.C. Palomares, P. Forget, D. Ryan, Maria Rosario Alonso, Antonia Barke, Ketan Bhatt, Anna Bjarnegård Sellius, Gertrude Buttigieg, Paul Cameron, Angela Cano Palomares, Duarte Correia, Beatriz Craveiro Lopes, Gustavo Fabregat, Maria Teresa Flor de Lima, Patrice Forget, Marisol García Penalta, Gunilla Goran, Liisa Jutila, Marja Kinnunen, Aleksandra Kotlinska-Lemieszek, Mateja Krzan, Françoise
Abstract not available
-
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms Ann. Oncol. (IF 50.5) Pub Date : 2024-02-02 Hermann Brenner, Tobias Niedermaier, Michael Hoffmeister
Abstract not available
-
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease Ann. Oncol. (IF 50.5) Pub Date : 2024-02-01 J.A. Ledermann, X. Matias-Guiu, F. Amant, N. Concin, B. Davidson, C. Fotopoulou, A. González-Martin, C. Gourley, A. Leary, D. Lorusso, S. Banerjee, L. Chiva, D. Cibula, N. Colombo, S. Croce, A.G. Eriksson, C. Falandry, D. Fischerova, P. Harter, F. Joly, C. Lazaro, C. Lok, S. Mahner, F. Marmé, C. Marth, W.G. McCluggage, I.A. McNeish, P. Morice, S. Nicum, A. Oaknin, J.A. Pérez-Fidalgo, S. Pignata, P
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics
-
European cancer mortality predictions for the year 2024 with focus on colorectal cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-01-28 C. Santucci, S. Mignozzi, M. Malvezzi, P. Boffetta, G. Collatuzzo, F. Levi, C. La Vecchia, E. Negri
We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We focused on mortality from colorectal cancer (CRC). Based on cancer death certification and population data from the World Health Organization and Eurostat databases from 1970 until the most available year, we predicted deaths and age-standardized rates (ASRs) for 2024 for all
-
Improved nationwide survival of sarcoma patients with a network of reference centers. Ann. Oncol. (IF 50.5) Pub Date : 2024-01-20 J.Y. Blay, N. Penel, T. Valentin, Ph Anract, F. Duffaud, A. Dufresne, B. Verret, A. Cordoba, A. Italiano, M. Brahmi, C. Henon, T. Amouyel, I. Ray-Coquard, G. Ferron, P. Boudou-Rouquette, C. Tlemsani, S. Salas, R. Rochwerger, M. Faron, E. Bompas, A. Le Cesne
We investigated the impact of the implementation of a network of reference centers for sarcomas (NETSARC) on the care and survival of sarcoma patients in France since 2010. Patients and methods NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB), funded by the French INCA since 2010. Its aims are to improve the quality of diagnosis
-
Inflammatory bowel disease and risk of malignant neoplasm in the small bowel Ann. Oncol. (IF 50.5) Pub Date : 2024-01-19 X.J. Luo, H.J. An, H.T. Gan
Abstract not available
-
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer Ann. Oncol. (IF 50.5) Pub Date : 2024-01-19 E. Harvey-Jones, M. Raghunandan, L. Robbez-Masson, L. Magraner-Pardo, T. Alaguthurai, A. Yablonovitch, J. Yen, H. Xiao, R. Brough, J. Frankum, F. Song, J. Yeung, T. Savy, A. Gulati, J. Alexander, H. Kemp, C. Starling, A. Konde, R. Marlow, M. Cheang, A.N.J. Tutt
Background Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple preclinically-validated mechanisms of resistance have been proposed, but their existence and relative frequency in clinical disease is unclear, as is how to target resistance. Patients and Methods Longitudinal mutation and methylation profiling of circulating
-
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes Ann. Oncol. (IF 50.5) Pub Date : 2024-01-18 Y. Loriot, D.P. Petrylak, A. Rezazadeh Kalebasty, A. Fléchon, R.K. Jain, S. Gupta, M. Bupathi, P. Beuzeboc, P. Palmbos, A.V. Balar, C.E. Kyriakopoulos, D. Pouessel, C.N. Sternberg, J. Tonelli, M. Sierecki, H. Zhou, P. Grivas, P. Barthélémy, S.T. Tagawa
Background Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate containing cytotoxic SN-38, the active metabolite of irinotecan. SG received accelerated US FDA approval for locally advanced (LA) or metastatic urothelial carcinoma (mUC) previously treated with platinum-based chemotherapy and a checkpoint inhibitor (CPI), based on Cohort 1 of the TROPHY-U-01 study. Mutations in the
-
-
-
Annals of Oncology – passing the baton, raising the bar Ann. Oncol. (IF 50.5) Pub Date : 2024-01-12 Thomas Powles
Abstract not available
-
Corrigendum to “Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child”: [Ann Oncol 34 (2023) 968–969] Ann. Oncol. (IF 50.5) Pub Date : 2024-01-08 R. Abelman, L.M. Spring, R.B. Corcoran, A. Bardia
Abstract not available
-
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702] Ann. Oncol. (IF 50.5) Pub Date : 2024-01-08 M. Burotto, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L. Herraez-Baranda, S.N. Liu, P. Chan, E. Shearer-Kang, X. Liu, N. Tosti, J.A. Zanghi, B. Leutgeb, E. Felip
Abstract not available
-
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma Ann. Oncol. (IF 50.5) Pub Date : 2023-12-28 N. Gavrielatou, E. Fortis, A. Spathis, M. Anastasiou, P. Economopoulou, G.R.P. Foukas, I.M. Lelegiannis, S. Rusakiewicz, I. Vathiotis, T.N. Aung, S. Tissot, A. Kastrinou, I. Kotsantis, E.M. Vagia, I. Panayiotides, D.L. Rimm, G. Coukos, K. Homicsko, P. Foukas, A. Psyrri
Background Programmed cell death protein 1(PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). PD-L1 is the only approved biomarker for patient selection; however, response rate is limited even among high expressors. Our primary objective was to investigate the association of immune-cell-related biomarkers in
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 Ann. Oncol. (IF 50.5) Pub Date : 2023-12-25 A.B. El-Khoueiry, J. Trojan, T. Meyer, T. Yau, I. Melero, M. Kudo, C. Hsu, T.-Y. Kim, S.-P. Choo, Y.-K. Kang, W. Yeo, A. Chopra, S. Soleymani, J. Yao, J. Neely, M. Tschaika, T.H. Welling, B. Sangro
Background Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced cohorts of CheckMate 040 are presented here. Patients and methods Patients received nivolumab
-
Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey Ann. Oncol. (IF 50.5) Pub Date : 2023-12-23 P. Comoli, G. Pentheroudakis, A. Ruggeri, U. Koehl, Lordick F, J.E. Mooyaart, J.D. Hoogenboom, A. Urbano-Ispizua, S. Peters, J. Kuball, N. Kröger, A. Sureda, C. Chabannon, J. Haanen, P. Pedrazzoli
Abstract not available
-
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) Ann. Oncol. (IF 50.5) Pub Date : 2023-12-23 M.A. Gouda, F. Janku, A. Wahida, L. Buschhorn, A. Schneeweiss, N. Abdel Karim, D. De Miguel Perez, M. Del Re, A. Russo, G. Curigliano, C. Rolfo, V. Subbiah
Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough macroscopic changes in tumor volume, which limits the usability of radiological response criteria in evaluating earlier stages of disease response and necessitates much time to lapse for gross changes to be notable
-
ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial. Ann. Oncol. (IF 50.5) Pub Date : 2023-12-22 B. Audinot, D. Drubay, N. Gaspar, A. Mohr, C. Cordero, P. Marec-Bérard, C. Lervat, S. Piperno-Neumann, M. Jimenez, L. Mansuy, M.-P. Castex, G. Revon-Riviere, A. Marie-Cardine, C. Berger, C. Piguet, K. Massau, B. Job, G. Moquin-Beaudry, M.-C. Le Deley, M.-D. Tabone, S. Abbou
Purpose Osteosarcoma stratification relies on clinical parameters and histological response. We developed a new personalized stratification using less invasive circulating tumor DNA (ctDNA) quantification. Patients and Methods Plasma from patients homogeneously treated in the prospective protocol OS2006, at diagnosis, before surgery and end of treatment, where sequenced using low passage whole genome
-
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† Ann. Oncol. (IF 50.5) Pub Date : 2023-12-13 S. Loibl, F. André, T. Bachelot, C.H. Barrios, J. Bergh, H.J. Burstein, L.M.J. Cardoso, L.A. Carey, S. Dawood, L. Del Mastro, C. Denkert, E.M. Fallenberg, P.A. Francis, H. Gamal-Eldin, K. Gelmon, C.E. Geyer, M. Gnant, V. Guarneri, S. Gupta, S.B. Kim, N. Harbeck
Abstract not available
-
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial Ann. Oncol. (IF 50.5) Pub Date : 2023-12-12 L.M. Spring, S.M. Tolaney, G. Fell, V. Bossuyt, R.O. Abelman, B. Wu, S. Maheswaran, L. Trippa, A. Comander, T. Mulvey, S. McLaughlin, P. Ryan, L. Ryan, E. Abraham, A. Rosenstock, A.C. Garrido-Castro, F. Lynce, B. Moy, S.J. Isakoff, N. Tung, E.A. Mittendorf, L.W. Ellisen, A. Bardia
Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results. Participants with early-stage TNBC received NA SG for four cycles. The primary objective was to assess pathological
-
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors Ann. Oncol. (IF 50.5) Pub Date : 2023-12-09 K.D. Lewis, K. Peris, A. Sekulic, A.J. Stratigos, L. Dunn, Z. Eroglu, A.L.S. Chang, M.R. Migden, S.-Y. Yoo, K. Mohan, E. Coates, E. Okoye, T. Bowler, J.-F. Baurain, O. Bechter, A. Hauschild, M.O. Butler, L. Hernandez-Aya, L. Licitra, R.I. Neves, M.G. Fury
-
Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 I.A. McNeish, B.J. Monk
Abstract not available
-
-
-
Annals of Oncology 2018-2023 Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 F. Andre
Abstract not available
-
The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 Seth A. Wander
Abstract not available
-
Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now? Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 A. D’Souza, J. King, L. Nappi, S. Daneshmand, C. Nichols, C. Kollmannsberger
Abstract not available
-
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 W.K. Jacky Lam, Guannan Kang, W.S. Winsome Wong
Abstract not available
-
Time to treat the climate and nature crisis as one indivisible global health emergency Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 K. Abbasi, P. Ali, V. Barbour, T. Benfield, K. Bibbins-Domingo, S. Hancocks, R. Horton, L. Laybourn-Langton, R. Mash, P. Sahni, W.M. Sharief, P. Yonga, C. Zielinski
Abstract not available
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2 Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 S. Damodaran, C.C. O’Sullivan, A. Elkhanany, I.C. Anderson, M. Barve, S. Blau, M.A. Cherian, J.A. Peguero, M.P. Goetz, P.V. Plourde, D.J. Portman, H.C.F. Moore
Background Acquired ESR1 mutations in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) drive treatment resistance and tumor progression; new treatment strategies are needed. Lasofoxifene, a next-generation, oral, endocrine therapy and tissue-specific ER antagonist, provided preclinical antitumor activity, alone or combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in ESR1-mutated
-
Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 M.P. Goetz, N.A. Bagegni, G. Batist, A. Brufsky, M.A. Cristofanilli, S. Damodaran, B.R. Daniel, G.F. Fleming, W.J. Gradishar, S.L. Graff, M.T. Grosse Perdekamp, E. Hamilton, S. Lavasani, A. Moreno-Aspitia, T. O’Connor, T.J. Pluard, H.S. Rugo, S.L. Sammons, L.S. Schwartzberg, D.G. Stover, E.N. Gal-Yam
Background Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, and has antitumor activity in ESR1-mutated xenografts. Patients and methods In this open-label, randomized, phase II, multicenter
-
Retraction notice to “CN5 - Examination of mobile applications on breast cancer”: [Annals of Oncology 30S5 (2019) v817] Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 A. Aydin, A. Gursoy
Abstract not available
-
Retraction notice to “CN17 - Using mobile-based health care applications outcomes: Mini systematic review”: [Annals of Oncology 30S5 (2019) v820] Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 A. Aydin, A. Gursoy
Abstract not available
-
Retraction notice to “CN104 - How should the symptoms be managed after breast cancer surgery? An example of mobile app”: [Annals of Oncology 30S5 (2019) v845] Ann. Oncol. (IF 50.5) Pub Date : 2023-12-10 A. Aydin, A. Gursoy
Abstract not available
-
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) Ann. Oncol. (IF 50.5) Pub Date : 2023-12-11 C. Saura, S. Modi, I. Krop, Y.H. Park, S.-B. Kim, K. Tamura, H. Iwata, J. Tsurutani, J. Sohn, E. Mathias, Y. Liu, J. Cathcart, J. Singh, T. Yamashita
Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1). We report updated cumulative survival outcomes
-
Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li Ann. Oncol. (IF 50.5) Pub Date : 2023-12-11 K.N. Chi
Abstract not available
-
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Ann. Oncol. (IF 50.5) Pub Date : 2023-12-06 F. Moik, J.M. Riedl, C. Ay
Abstract not available
-
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial Ann. Oncol. (IF 50.5) Pub Date : 2023-12-05 J. Ferdinandus, H. Müller, C. Damaschin, A.S. Jacob, J. Meissner, F. Krasniqi, U. Mey, D. Schöndube, J. Thiemer, S. Mathas, J. Zijlstra, R. Greil, M. Feuring-Buske, J. Markova, J.U. Rüffer, C. Kobe, H.-T. Eich, C. Baues, M. Fuchs, P. Borchmann, K. Behringer
Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin’s lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery
-
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer Ann. Oncol. (IF 50.5) Pub Date : 2023-12-05 W. Xie, P. Ravi, M. Buyse, S. Halabi, P. Kantoff, O. Sartor, H. Soule, N. Clarke, J. Dignam, N. James, K. Fizazi, S. Gillessen, N. Mottet, L. Murphy, W. Parulekar, H. Sandler, B. Tombal, S. Williams, C.J. Sweeney
Prior work from the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) consortium (ICECaP-1) demonstrated that metastasis-free survival (MFS) is a valid surrogate for overall survival (OS) in localized prostate cancer (PCa). This was based on data from patients treated predominantly before 2004, prior to docetaxel being available for the treatment of metastatic castrate-resistant prostate
-
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis Ann. Oncol. (IF 50.5) Pub Date : 2023-12-02 J.M. Piulats, C. Watkins, M. Costa-García, L. del Carpio, S. Piperno-Neumann, P. Rutkowski, J.C. Hassel, E. Espinosa, L. de la Cruz-Merino, S. Ochsenreither, A.N. Shoushtari, M. Orloff, A.K.S. Salama, H.M. Goodall, J.-F. Baurain, P. Nathan
Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator’s choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; = 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively. In the single-arm GEM1402 ( = 52), the 1-year OS rate for nivolumab plus